Abstract: A method for adjusting hardness of a stick-shaped base material including a lipid peptide compound. A method for adjusting hardness of a gelled solid base material for skin external application including a surfactant, water, and lipid peptide compound including compounds of formulae (1) or similar, wherein R1 is a C9-23 aliphatic group, R2 is a hydrogen atom or similar, and R3 is a —(CH2)n-X group, n is a number from 1 to 4, and X is amino group, the method including adding a pH adjuster to a solution in which the material is dissolved, or a solution including a surfactant, water, and lipid peptide compound including at least one of compounds of formulae (1) to (3) or pharmaceutically usable salts thereof, to adjust the pH of the solution to a weak acidic to neutral range, causing gelation of the solution to form a solid base material for skin external application.

Abstract: Peptides, topical compositions, and methods of improving health and/or appearance of human integuments, such as keratinous surfaces and fibers are provided. The peptides have from 3-12 amino acid residues and comprise the sequence YNT (SEQ ID NO: 1) or PVG (SEQ ID NO: 2).

Abstract: Provided herein are oral care compositions comprising partially hydrolyzed plant protein, which are useful in methods of repairing or inhibiting dental erosion, promoting dental remineralization, and/or enhancing the anti-cavity effects of fluoride.

Abstract: A convenient all-in-one kit for cleansing the eyelids and treating bacterial blepharitis contains one or more fabric pads pre-moistened with a therapeutically effective amount of a hypochlorous acid-based composition. The kit can further include an eyelid cleanser composition as a kit component. The eyelid cleanser composition can be selected from a group consisting of a solution, a foam, a gel, a spray, a lotion, a suspension, an emulsion, an ointment and combinations thereof. The kit can further include one or more fabric pads or wipes impregnated/pre-moistened with the eyelid cleanser composition.

Abstract: Hair treatment agents containing at least one anionic surfactant, at least one amphoteric and/or nonionic surfactant, at least one cationic polysaccharide polymer, hexetidine, at least one organic acid and at least one lipid component reduce or prevent the washing-out of color from colored hair.

Abstract: The present disclosure relates to a sprayable gel composition, comprising (a) from about 0.08% to about 1.8% by weight of a polysaccharide, (b) from about 0.002% to about 0.08% by weight of a divalent alkaline earth cation, (c) from about 0.1% to about 30% by weight of a humectant, (d) from 0% to about 30% by weight of an emollient, and (e) from about 40% to about 95% by weight of a cosmetically acceptable carrier, wherein the weight percentages are based on the total weight of all components of the sprayable gel composition, and to a method of treating hair in need of a conditioning treatment.

Abstract: Compositions including polycarbodiimide and derivatives thereof together with latex polymers and derivatives thereof to enhance the quality of the keratinous substrates. The present invention relates to a cosmetic treatment and process for treating keratinous materials, in particular for hair-care and hair-styling. A method of styling or shaping hair is also disclosed. Compositions are provided for nail treatment and processes including polycarbodiimide and latex actives for application in a nail treatment that is a single step or at least two sequential steps, the compositions and processes providing one or more of improved adhesion, water resistance, and shine through crosslinking between the actives, thereby imparting long wear, good shine, nail protection, and easy removal.

Abstract: A clear coating composition for use over nail polish.

Abstract: The disclosure describes compositions for dental varnishes, methods of making the compositions, and methods of using the compositions, such as in the treatment and prevention of hypersensitivity in teeth.

Abstract: The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of Argania spinosa kernel extract, dill extract, Myrciaria dubia fruit extract, and Croton lechleri extract and/or Morus alba fruit extract. This combination can be used to create topical skin compositions that reduce the appearance of loose, sagging, and/or flaccid skin, and/or improve facial contouring.

Abstract: A preparation method for camellia extract includes the following steps: 1) Removing impurities from fresh camellia and/or fresh camellia buds, cutting the fresh camellia and/or fresh camellia buds into small sections for use as raw materials; 2) Placing a certain quantity of raw materials into a ultrasonic vessel, adding in a solvent having a mass ratio of 1:3 to 1:30 to form a mixture, uniformly stirring the mixture, and then adding in a certain amount of inorganic acid and/or organic acid to adjust the pH value to 1.3 to 3.0, then soaking the raw materials for 10 minutes to 30 minutes; 3) Performing ultrasonic treatment for 30 minutes to 60 minutes, controlling the ultrasonic frequency to be 20 KHz to 25 KHz, the ultrasonic power to be 1000 W to 2000 W, the ultrasonic temperature to be 15° C. to 50° C., then performing filtration, sterilization and detection to obtain camellia extract.

Abstract: The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.

Abstract: The present disclosure generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.

Abstract: Peptide hydrogels having a self-assembling, 3-dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and optionally albumin. The peptide comprises (consists of) a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, hemostatic agents, as well as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage.

Abstract: The present invention relates to a product consisting of a conglomerate of collagen, in the form of the partly hydroyzed industrial derivative thereof called gelatine, and an amorphous micronized drug, characterized by a high bioavailability of the micronized active ingredient and a safety of use of the same deriving from the protective action of collagen against the harmful effects of contact with the active ingredient.

Abstract: Several methods for the preparation of an amorphous powder comprising a 1:1 stoichiometric mixture of the trisodium salts of Valsartan and Sacubitril are described, as well as the resulting amorphous powder, pharmaceutical compositions containing it, and their use in the treatment of essential hypertension and/or cardiac failure.

Abstract: This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders.

Abstract: Disclosed are soft gelatin capsules comprising a gelatin shell, a plasticiser, water, and optionally a calcium salt and a filling containing a dispersed or solubilised medicament comprising gelatin with gelling power, hydrolysed gelatin, glycerol, water, pectin and gellan gum. The formulations according to the invention allow gradual release of the active ingredient, regardless of pH.

Abstract: Methods for forming multiphasic microparticles by using wettability engendered template self-assembly (WETS) techniques are provided. A template is used that defines wettable regions to polar and non-polar liquids and non-wettable regions to polar and non-polar liquids. A first liquid is applied to the template and forms a solid or semi-solid release layer. A second liquid is applied over the release layer to form a solid or semi-solid first layer and a third liquid is applied over the first layer to form a solid or semi-solid second layer. The first layer and the second layer can be released from the template by removing the release layer from the template with a treatment agent to form multiphasic microparticles. Methods for making the templates and multiphasic micro particles are also provided.

Abstract: The present invention provides nucleic acid-containing lipid nanoparticles containing a lipid (lipid A) which has a hydrophilic unit having a single quaternary ammonium group, and three independent, optionally substituted hydrocarbon groups, a lipid derivative or fatty acid derivative of a water-soluble polymer, and a nucleic acid.

Abstract: The present invention provides compositions (e.g., nanoparticles) comprising a conjugated polyethyleneimine (PEI) polymer (a “conjugated lipomer”), or a pharmaceutically acceptable salt thereof, and a lipid-PEG conjugate, wherein the conjugated lipomer of Formula (I) contains one or more groups of the formula (iii). Compositions of the invention are useful for the delivery of active agents, for example, for the treatment of disease.

Abstract: The present invention provides compositions and methods for the delivery of therapeutics to a cell or subject.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.

Abstract: Devices and systems for delivering an agent to the skin of a subject comprise an anhydrous agent (e.g. a pharmaceutical agent or a cosmetic agent), and an anhydrous heating component and a reservoir containing a solvent. When in use solvent released from the reservoir hydrates the anhydrous agent to produce a solution and hydrates the anhydrous heating component which reacts exothermically thereby heating the solution. The devices and systems enable the transdermal delivery of pharmaceutical and cosmetic agents.

Abstract: A pimarane diterpenoid, having the following structure: or a tautomer thereof in which R1 and R2 are independently selected from —H, C1-10 alkyl, C1-10 alkoxy, C1-10 alkenyl, C1-10 alkenoxy, —OH, —OAc, —CHO, -Ph, —OC6H5, —OC6H4OH, —COC6H5, —OCONH2, —OCONHCH3, —OCOC6H4NH2, —NH2, or ?O based on an isolate from the plant Hymenocrater elegans is utilized in the prevention of growth and development of pathogenic cells, e.g., cancer cells. The compound shows efficacy in treatment and prevention of a wide range of cancer types as well as other neoplastic diseases as a chemo-preventative, a primary or secondary cytotoxic agent, a sensitizer for other therapies, or one component of a combinatorial treatment.

Abstract: Methods and compositions are described for use in encouraging angiogenesis and skin healing as may be utilized in wound treatment as well as in encouragement of angiogenesis in disease. Compositions include an effective amount of a natural pimarane diterpenoid extract of Hymenocrater elegans, or a derivative, analogue, or homolog thereof. Compounds based upon this natural extract have been found to be highly effective in vascular formation and skin closure while exhibiting low toxicity.

Abstract: The invention relates compositions and methods for treating pathological lung conditions using whole-grain flaxseed or flaxseed lignans. Specifically, the invention relates to the dietary use of flaxseed lignans.

Abstract: The present invention relates to specific ?-hydroxyketones of the formula (I) for use in the prevention and/or treatment of photodermatoses and to the use of specific ?-hydroxyketones of the formula (I) as active ingredient in typical compositions for the prevention and/or non-therapeutic treatment of photodermatoses, in particular of polymorphic light eruption.

Abstract: Methods for modulating miRNA148a levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III in order to increase miRNA148a levels, or providing to the cells a curcumin II-enriched composition in order to reduce miRNA148a levels. In addition, compositions for elevating miRNA148a levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 5% curcumin III and a pharmaceutically-acceptable solvent, filler, or carrier. Similarly, compositions for reducing miRNA148a levels in a plurality of cells are disclosed, which include a curcumin II-enriched composition and a pharmaceutically-acceptable solvent, filler, or carrier.

Abstract: The present invention relates to a composition for preventing and/or treating cardiovascular and cerebrovascular diseases, a method for preparing the same, and use thereof, wherein the composition comprises at least two of docosahexaenoic acid or an ester thereof, coenzyme Q10, lipoic acid and phospholipid. The composition is used for preparing a dietary supplement or health food, preferably, for preparing a dietary supplement or health food for preventing and/or treating dyslipidemia or cardiovascular and cerebrovascular diseases.

Abstract: In some aspects, the disclosure provides methods of modulating the level of proteasome inhibitor resistance of a cell, the methods comprising manipulating the level of expression or activity of a subunit of the 19S proteasome in the cell. In some aspects, cells in which the level of a 19S subunit is modulated, e.g., reduced, are provided. In some aspects, methods of identifying agents that reduce proteasome inhibitor resistance are provided. In some aspects, methods of classifying cancers according to predicted proteasome inhibitor resistance are provided. In some aspects, methods of killing or inhibiting proliferation of cancer cells, e.g., proteasome inhibitor resistant cancer cells, are provided. In some aspects, methods of treating cancer, e.g., proteasome inhibitor resistant cancer, are provided.

Abstract: The present invention includes compositions for treating cancer, and methods using same. In certain embodiments, the compositions of the invention comprise a histone deacetylase inhibitor (HDACi), a cyclodextrin, water, optionally a polyalkylene glycol, and optionally dimethyl sulfoxide (DMSO). In other embodiments, the compositions of the invention comprise a HDACi, a cyclodextrin, water, a polyalkylene glycol, and DMSO.

Abstract: This invention relates to preparations comprising a butyrate salt for enteral administration for use in the treatment of conditions and diseases that are not diseases or conditions of the intestine and/or are associated with systemic inflammation. Preparations comprising a butyrate salt for enteral administration were found useful in the treatment of osteoarthritis, arteriosclerosis, rheumatism, psoriasis, multiple sclerosis, Alzheimer's' disease, Parkinson's disease, migraine, autism, depression, impaired kidney functioning, idiopathic subfertility, recurrent abortion, recurrent implantation failure, hangovers, and gout.

Abstract: The invention refers to an antimicrobial, exfoliating and seboregulating hydrosoluble composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid), which acts removing bacteria affecting the skin including those caused by acne, said composition also provides deep cleansing, exfoliating action, reduces epidermal cohesion facilitating cellular change, preventing the occurrence of several forms of acne in the skin and additionally producing seboregulating effects by avoiding blockage of sebaceous glands.

Abstract: A drug combination with antitumor effects, contains styrene acid derivatives and antitumor medicaments with same or different specifications of unit preparations that can be simultaneously or separately administrated, as well as pharmaceutically acceptable carriers. The joint use of trans-styrene acid derivatives and antitumor drugs provides synergistic action, and the use of trans-styrene acid derivatives combined with a part of antitumor drugs can further exert the toxicity attenuation effects, showing a good clinical application prospect.

Abstract: Disclosed are methods for treating a subject having or at risk of developing a disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath, by administering an effective amount of sobetirome or a sobetirome prodrug and one or more PPAR activators to the subject. Also disclosed are pharmaceutical compositions in unit dosage form containing an effective amount of sobetirome or a sobetirome prodrug, one or more PPAR activators, and a pharmaceutically acceptable excipient.

Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.

Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive compulsive disorder, anxiety disorder or a condition characterised by one or more symptoms of a obsessive compulsive disorder or an anxiety disorder.

Abstract: Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions containing defined ratios of 5,11,14-eicosatrienoic acid to one or more of: 5,9,12-octadecatrienoic acid; 7,11,14-eicosatrienoic acid; 5,8,11,14-eicosatetraenoic acid; 9,12-octadecadienoic acid; 9-octadecenoic acid; 14-methyl hexadecanoic acid; 11,14 eicosadienoic acid, 5,9-octadecadienoic acid; 5,11-octadecadienoic acid; 9,12,15-octadecatrienoic acid; 5,8,11,14,17-eicosapentaenoic acid; 7,10,13,16,19-docosapentaenoic acid; and 4,7,10,13,16,19-docosahexaenoic acid.

Abstract: The disclosure includes a method of inducing direct reprogramming (transdifferentiation) into non-oncogenic cells accompanied by tumor cell apoptosis in human tumor cells using a small molecule composition, based on the mechanism of chemical-induction of direct cellular reprogramming. The disclosure also includes a small molecule composition used for the method, and culture media and agents prepared from the composition.

Abstract: A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); wherein the ratio of MCT-C8 to MCT-C10 is from 10:90 to 90:10 (mol/mol) and wherein the combined amount of MCT-C8 and MCT-C10 make up at least 50 mol % of the MCTs in the composition.

Abstract: The present invention refers to a glycerol ester composition comprising glyceryl monovalerate, for use in preventing and/or alleviating bacterial inflammation in a monogastric animal (including human) by inhibiting the adhesion of pathogenic bacteria to the intestinal lumen of said animal. The present invention also refers to a therapeutic method for promoting the renewal and growth of epithelial cells in the small intestine of a monogastric animal (including human), the method comprising the step of distributing a glycerol ester composition comprising glyceryl monovalerate to said animal.

Abstract: Abietane diterpenoids developed from a 7-acetoxyroyleanone that has been isolated from the root of the plant Salvia leriifolia are utilized in the prevention of growth and development of pathogenic cells, e.g., cancer cells. The 7-acetoxyroyleanones show efficacy in treatment and prevention of a wide range of cancer types as well as other neoplastic diseases as a chemo-preventative, a primary or secondary cytotoxic agent, a sensitizer for other therapies, or one component of a combinatorial treatment.

Abstract: The invention relates to a composition containing pheromones comprising a carrier solvent, and to the use thereof for preventing and/or treating the behavioural or medical problems linked to the stress of non-human mammals. The invention also relates to a device for diffusing such a composition into the ambient air, and to a kit comprising said composition.

Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a methanesulfonylalkylnitrile compound, or a pharmaceutically acceptable salt or solvate thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering a methanesulfonylalkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Abstract: The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence, urge urinary incontinence, mixed incontinence, and pelvic floor disorders by administering a SARM compound of the invention.

Abstract: A ceramide-generating anticancer agent or treatment, and/or a ceramide degradation inhibitor, or a pharmaceutically acceptable salt or ester thereof, for use in the prevention, treatment, or amelioration of cancer or tumors of the hematopoietic and lymphoid tissues.

Abstract: A cannabis-based flavonoid pharmaceutical composition including any one or more selected from among the group of Cannflavin A, Cannflavin B. Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside and their derivatives selected from among the group of Geraldol, Rhamnetin, Isorhamnetin, Rhamnazin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and histone acetylases. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include but are not limited to brain, breast, colon, renal liver, lung, pancreatic, pigmented villonodular synovitis, prostate, leukemia, melanomam, tenosynovial giant cell tumor, as well as any other cancers that overexpress the oncogenic factors inhibited, by the cannabis flavonoids or their derivatives herein identified.

Abstract: The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.